Matrix metalloproteinase‐9 concentrations in critically ill patients
- 1 August 2001
- journal article
- research article
- Published by Wiley in Anaesthesia
- Vol. 56 (8) , 729-732
- https://doi.org/10.1046/j.1365-2044.2001.02083.x
Abstract
Matrix metalloproteinase‐9 is involved in the processing of cytokines during sepsis. We studied 10 critically ill patients within 12 h of fulfilling the American Consensus Conference criteria for severe sepsis and compared the results with 12 critically ill non‐septic control patients and eight healthy subjects. Total matrix metalloproteinase‐9 concentrations were measured on days 1, 2 and 3. The median admission Acute Physiological and Chronic Health Evaluation II score was 19.5 (range 13–27) in the septic patients and 20.5 (range 7–28) in the non‐septic patients. Four patients from each group died within 28 days. Matrix metalloproteinase‐9 concentrations were elevated significantly in both groups of patients compared with healthy subjects (p = 0.0004) but there was no difference between patients with and without sepsis. Matrix metalloproteinase‐9 levels did not change with time, and there was no difference between survivors and those who died. We conclude that matrix metalloproteinase‐9 represents a non‐specific marker of systemic inflammation.Keywords
This publication has 11 references indexed in Scilit:
- Modulation of Plasma Metalloproteinase-9 Concentrations and Peripheral Blood Monocyte mRNA Levels in Patients with Septic Shock: Effect of Fiber-Immobilized Polymyxin B TreatmentThe Lancet Healthy Longevity, 1998
- Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseasesMolecular Medicine Today, 1998
- Matrix metalloproteinasesBritish Journal of Surgery, 1997
- A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsisCritical Care Medicine, 1996
- Markedly Elevated Serum MMP-9 (Gelatinase B) Levels in Rheumatoid Arthritis: A Potentially Useful Laboratory MarkerClinical Immunology and Immunopathology, 1996
- Matrix Metalloproteinases and Cardiovascular DiseaseCirculation Research, 1995
- Plasma Levels of Cytokines in Primary Septic Shock in Humans: Correlation with Disease SeverityThe Journal of Infectious Diseases, 1995
- Processing of tumour necrosis factor-α precursor by metalloproteinasesNature, 1994
- Serum Cytokine Levels in Human Septic ShockChest, 1993
- Plasma Tumor Necrosis Factor in Patients with Septic Shock: Mortality Rate, Incidence of Adult Respiratory Distress Syndrome, and Effects of Methylprednisolone AdministrationAmerican Review of Respiratory Disease, 1989